Monash IVF Group achieves 14.7% FY23 Underlying NPAT increase, signalling FY24 optimism

Monash IVF Group Limited (ASX: MVF) has unveiled its financial results for the fiscal year 2023, characterized by strong growth primarily driven by its Domestic Assisted Reproductive Services (ARS) and Women's Imaging divisions, tempered by a weaker performance in the International ARS sector.

Monash IVF is positioned for revitalization in the industry, supported by recent market share gains and an increase in patient registrations, pointing towards a promising trajectory as it enters FY24.

Key highlights for FY23 include:

- A significant 11.1% growth in revenue to reach AU$213.6 million.

- A robust 14.7% increase in Underlying Group NPAT, totaling AU$25.5 million.

- Underlying Group EBITDA growth of 11.0%, reaching AU$53.4 million, with a consistent EBITDA Margin of 25%.

- The announcement of a final fully franked dividend of 2.2 cents per share.

Customer Notice:

Nextgen Global Services Pty Ltd trading as Kapitales Research (ABN 89 652 632 561) is a Corporate Authorised Representative (CAR No. 1293674) of Enva Australia Pty Ltd (AFSL 424494). The information contained in this website is general information only. Any advice is general advice only. No consideration has been given or will be given to the individual investment objectives, financial situation or needs of any particular person. The decision to invest or trade and the method selected is a personal decision and involves an inherent level of risk, and you must undertake your own investigations and obtain your own advice regarding the suitability of this product for your circumstances. Please be aware that all trading activity is subject to both profit & loss and may not be suitable for you. The past performance of this product is not and should not be taken as an indication of future performance.

Kapitales Research, Level 13, Suite 1A, 465 Victoria Ave, Chatswood, NSW 2067, Australia | 1800 005 780 | info@kapitales.com